Literature DB >> 12872287

Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat.

Paola Fadda1, Maria Scherma, Alessandra Fresu, Maria Collu, Walter Fratta.   

Abstract

Evidence recently provided has suggested a specific involvement of the GABAergic system in modulating positive reinforcing properties of several drugs of abuse through an action on mesolimbic dopaminergic neurons. The GABA(B) receptor agonist baclofen has been proposed as a potential therapeutic agent for the clinical treatment of several forms of drug addiction. In the present study, using the in vivo microdialysis technique, we investigated the effect of baclofen on nicotine, cocaine, and morphine-induced increase in extracellular dopamine (DA) levels in the shell of the nucleus accumbens, a brain area supposedly involved in the modulation of the central effects of several drugs of abuse, of freely moving rats. As expected, nicotine (0.6 mg/kg s.c.), morphine (5 mg/kg s.c.), and cocaine (7.5 mg/kg i.p.) administration in rats induced a marked increase in extracellular DA concentrations in the nucleus accumbens, reaching a maximum value of +205 +/- 8.4%, +300 +/- 22.2%, and +370 +/- 30.7%, respectively. Pretreatment with baclofen (1.25 and 2.5 mg/kg i.p.) dose-dependently reduced the nicotine-, morphine-, and cocaine-evoked DA release in the shell of the nucleus accumbens. Furthermore, baclofen alone did not elicit changes in basal DA extracellular levels up to 180 min. Taken together, our data are in line with previous reports demonstrating the ability of baclofen to modulate the mesolimbic DAergic transmission and indicate baclofen as a putative candidate in the pharmacotherapy of polydrug abuse. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12872287     DOI: 10.1002/syn.10238

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  72 in total

Review 1.  Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability.

Authors:  Tomas Palomo; R M Kostrzewa; R J Beninger; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 2.  Novel pharmacotherapeutic treatments for cocaine addiction.

Authors:  Daryl Shorter; Thomas R Kosten
Journal:  BMC Med       Date:  2011-11-03       Impact factor: 8.775

Review 3.  [New developments in the pharmacotherapy of cocaine dependence].

Authors:  G Wiesbeck; K Dürsteler-MacFarland
Journal:  Nervenarzt       Date:  2006-09       Impact factor: 1.214

4.  Accumbens neurochemical adaptations produced by binge-like alcohol consumption.

Authors:  Karen K Szumlinski; Mahdi E Diab; Raquel Friedman; Liezl M Henze; Kevin D Lominac; M Scott Bowers
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

5.  The Effects of Morphine, Baclofen, and Buspirone Alone and in Combination on Schedule-Controlled Responding and Hot Plate Antinociception in Rats.

Authors:  Jenny L Wilkerson; Jasmine S Felix; Luis F Restrepo; Mohd Imran Ansari; Andrew Coop; Lance R McMahon
Journal:  J Pharmacol Exp Ther       Date:  2019-06-24       Impact factor: 4.030

6.  The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats.

Authors:  Brendan M Walker; George F Koob
Journal:  Alcohol Clin Exp Res       Date:  2007-01       Impact factor: 3.455

Review 7.  Microdialysis and the neurochemistry of addiction.

Authors:  Mary M Torregrossa; Peter W Kalivas
Journal:  Pharmacol Biochem Behav       Date:  2007-09-12       Impact factor: 3.533

8.  Gene expression differences in mice divergently selected for methamphetamine sensitivity.

Authors:  Abraham A Palmer; Miguel Verbitsky; Rathi Suresh; Helen M Kamens; Cheryl L Reed; Na Li; Sue Burkhart-Kasch; Carrie S McKinnon; John K Belknap; T Conrad Gilliam; Tamara J Phillips
Journal:  Mamm Genome       Date:  2005-05       Impact factor: 2.957

9.  Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations.

Authors:  Andrés P Varani; Ester Aso; Lirane Machado Moutinho; Rafael Maldonado; Graciela N Balerio
Journal:  Psychopharmacology (Berl)       Date:  2014-02-20       Impact factor: 4.530

10.  The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes.

Authors:  S Rossi; S Singer; E Shearman; H Sershen; A Lajtha
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.